Navigation Links
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment
Date:12/4/2010

FRIDAY, Dec. 3 (HealthDay News) -- Use of androgen suppression therapy for low-risk prostate cancer fell after doctors starting receiving lower Medicare payments for the treatment, but use of the treatment for patients with metastatic prostate cancer stayed steady, a new study shows.

The findings, published online Dec. 3 in the Journal of the National Cancer Institute, suggest the payment cuts may have reduced over-treatment of low-risk prostate cancer, the researchers said.

Between 1991 and 1999, the use of the therapy for prostate cancer increased more than threefold among patients with metastatic prostate cancer (cancer that has spread) and low-risk prostate cancer, even though the treatment has not been shown to improve survival in patients with low-risk disease.

When Medicare physician reimbursements for androgen therapy were reduced by 64 percent between 2004 and 2005, use of the therapy for men with low-risk prostate cancer fell by 40 percent while there was no statistically significant change among men with metastatic prostate cancer, the study found.

The researchers looked at factors other than Medicare payment cuts that could account for the findings, such as growing awareness of the therapy's side effects and increasing use of longer-acting treatments.

However, they concluded that the decline in use of androgen therapy for low-risk prostate cancer patients "likely represents a real effect of reimbursement change and not physician awareness of clinical evidence," wrote Dr. Sean P. Elliott, of the University of Minnesota, and colleagues in a news release from the journal.

More information

The American Urological Association has more about hormone therapy for prostate cancer.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, news release, Dec. 3, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts
2. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
3. Medicare Part D Changes Not Overwhelming, Experts Say
4. Study shows drop in unnecessary care after Medicare reimbursement cut
5. Use of Prostate Cancer Treatment Fell When Medicare Paid Docs Less
6. Study identifies flaws in Medicare prescription drug program
7. Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs
8. New Medicare model guidelines for benefit years 2012-2014 in development
9. Drug coverage under Medicare leads to increased use of antibiotics
10. Regional variation in health-care spending and utilization higher in Medicare than private sector
11. Study: Medicare policy may account for growing length of hospice stays in nursing homes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment
(Date:9/26/2017)... ... September 26, 2017 , ... Atmosera , a ... Management as a Service (RMaaS) to automate the deployment of websites and ... companies, e-tailers, and web development agencies who want to improve time-to-revenue with a ...
(Date:9/26/2017)... ... , ... As the holiday season nears, best deals online website, ... to find tips and stories for products and services savings. With a lot of ... deals. The deals are organized by categories so can easily find what you’re looking ...
(Date:9/26/2017)... Falls Church, VA (PRWEB) , ... September 26, 2017 , ... ... FDAnews and Cerulean Associates LLC **, Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity ... its investigators: “If initial findings indicate the firm’s electronic records may not be trustworthy ...
(Date:9/26/2017)... ... September 26, 2017 , ... Autism Learning ... Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, will be the ... Aspire provides center based Autism services in Broomfield and will continue to operate ...
(Date:9/26/2017)... ... September 26, 2017 , ... The Organizing Committee ... tactical plans for Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. ... named vice president, Charles Gardner, (ChemImage Corporation) and selected chairs. , ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... BioLife Solutions , Inc. (NASDAQ: BLFS ), the ... and tissue hypothermic storage and cryopreservation freeze ... and CEO, will be presenting at two investment conferences in ... th Annual Global Investment Conference on Tuesday, September 12th, ... conference is being held at the New York Palace Hotel ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: